Cover Image
市場調查報告書

全球癌症治療用單株抗體市場:成長、趨勢、預測 (2015年∼2020年)

Global Cancer Monoclonal Antibodies Market - Growth, Trends, Forecasts (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 353907
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症治療用單株抗體市場:成長、趨勢、預測 (2015年∼2020年) Global Cancer Monoclonal Antibodies Market - Growth, Trends, Forecasts (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 205 Pages
簡介

全球癌症治療用單株抗體市場,2015年達到270億美元,預計2015年∼2020年以8∼15%的年複合成長率成長。

本報告提供全球癌症治療用單株抗體市場相關調查分析,市場概要,推動市場要素、阻礙因素、機會,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 應用
  • 技術概要
  • 新的發展
  • 產業價值鏈分析
  • 產品生命週期分析
  • 產品基準
  • 投資分析
  • 波特的五力分析

第6章 推動因素、阻礙因素、機會、課題分析

  • 推動市場要素
  • 阻礙市場要素
  • 市場課題

第7章 市場區隔

  • 各應用
  • 單株抗體的各類型
  • 使用單株抗體的複合癌症治療

第8章 市場區隔 (各地區) :各地區的佔有率與預測

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

第9章 競爭情形

  • M&A分析
  • 專利分析
  • 課題

第10章 主要供應商分析

  • Amgen Inc.
  • Bristol-Meyer Squibb
  • GlaxoSmithKline
  • Roche Holding
  • Spectrum Pharmaceuticals
  • Merck & Co. Inc.
  • Eli Lilly & co.
  • ImmunoGen Inc.
  • Seattle Genetics
  • Janssen Biotech Inc.
  • Genmab
  • Novartis AG

第11章 投資機會預測

第12章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The global melanoma diagnostics and therapeutics market was valued at USD 2,662 million in 2015 and is expected to reach USD 5,450 million by 2020.

Global Melanoma Diagnostics and Therapeutics Market-Market Dynamics

The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities. The report details various factors driving and restraining the market, some of which are listed below.

Drivers

Increase in melanoma cases

Approval and uptake of premium-priced products

Effective immunotherapies

Label extension of current therapies into the new settings

Government initiatives

Technological advancements

Restraints

Lack of awareness in some developing regions

High cost associated with the therapy

Economic crisis

Regulatory issues

The market for melanoma diagnostics and therapeutics can be segmented based on the cancer type, cancer stage, diagnosis, treatment, and geography. On the basis of cancer type, the market is segmented into superficial, nodular, lentigo maligna, acral lentiginous and amelanotic melanoma. On the basis of the cancer stage, the market is segmented into Stage 0, Stage I, Stage II, Stage III, and Stage IV. Based on the diagnosis, the market is segmented into dermatoscopy, sentinel lymph node biopsy, X-rays, blood tests, CT scan, and ultrasound. Treatments for melanoma have been segmented into treatment for early stage melanoma (Excision and Mohs surgery) and treatment for advanced stage melanoma (chemotherapy, biological therapy, targeted therapy, radiotherapy, targeted therapy, immune therapy, lymphadenectomy). On the basis of geography, the market is segmented into North America, Europe, and Asia-Pacific.

a€

Some of the key players in the market are:

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

GlaxoSmithKline

Roche

What the Report Offers

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Table of Contents

1. Introduction

  • 1.1 Report description
  • 1.2 Research methodology

2. Executive summary

3. Market overview

  • 3.1 Market definition
  • 3.2 Market drivers
    • 3.2.1 Increasing incidences of melanoma cases
    • 3.2.2 The approval and uptake of premium-priced products
    • 3.2.3 Effective immunotherapies
    • 3.2.4 Label extension of current therapies into the new settings
    • 3.2.5 Government initiatives
  • 3.3 Market restraints
    • 3.3.1 Lack of awareness in some developing regions
    • 3.3.2 High cost associated with the therapy
    • 3.3.3 Economic crisis
    • 3.3.4 Regulatory issues
  • 3.4 Market opportunities
  • 3.5 Market threats

4. Portera€™s five force analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Degree of competition
  • 4.4 Threat of substitution
  • 4.5 Threat of new entrants

5. Market segmentation

  • 5.1 By cancer type
    • 5.1.1 Superficial spreading melanoma
    • 5.1.2 Nodular melanoma
    • 5.1.3 Lentigno maligna melanoma
    • 5.1.4 Acral lentiginous melanoma
    • 5.1.5 Amelanotic melanoma
    • 5.1.6 Others
      • 5.1.6.1 Cutaneous malignant melanoma
      • 5.1.6.2 Melanoma of vulva
      • 5.1.6.3 Vaginal melanoma or melanoma of black passage
  • 5.2 By cancer stage
    • 5.2.1 Stage 0
    • 5.2.1 Stage I
    • 5.2.1 Stage II
    • 5.2.1 Stage III
    • 5.2.1 Stage IV
  • 5.3 By diagnosis
    • 5.3.1 Dermatoscopy
    • 5.3.2 Sentinel lymph node biopsy
    • 5.3.3 Blood Tests
    • 5.3.4 X-rays
    • 5.3.5 Ultrasound
    • 5.3.6 CT Scan
  • 5.4 By treatment
    • 5.4.1 For early melanoma
      • 5.4.1.1 Surgery
      • 5.4.1.1.1 Excision
      • 5.4.1.1.2 Mohs surgery
    • 5.4.2 For advanced melanoma
      • 5.4.2.1 Chemotherapy
      • 5.4.2.2 Biological therapy
      • 5.4.2.3 Radiotherapy
      • 5.4.2.4 Targeted therapy
      • 5.4.2.5 Immune therapy
      • 5.4.2.6 Surgery
      • 5.4.2.6.1 Lymphadenectomy
  • 5.5 By geography
    • 5.5.1 North America
      • 5.5.1.1 US
      • 5.5.1.2 Canada
    • 5.5.2 Europe
      • 5.5.2.1 UK
      • 5.5.2.2 Germany
      • 5.5.2.3 Scandinavian Regions
      • 5.5.2.4 Italy
      • 5.5.2.5 France
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 India
      • 5.5.3.2 China
    • 5.5.3..3 Japan
    • 5.5.3. 4 Singapore
      • 5.5.3.5 Rest of Asia-Pacific

6. Competitive landscape

7. Company profiles

  • 7.1 Abbott Diagnostics
  • 7.2 Agilent Technologies
  • 7.3 Roche
  • 7.4 GlaxoSmithKline
  • 7.5 AstraZeneca
  • 7.6 Bristol-Myers Squibb
  • 7.7 Eli Lilly
  • 7.8 Merck
  • 7.9 Novartis
  • 7.10 Pfizer
  • 7.11 Sanofi
  • 7.12 Qiagen N.V. Company
  • 7.13 Teva Pharmaceuticals

8. Appendix

  • 8.1 Abbreviations
  • 8.3 Bibliography
  • 8.4 Disclaimer
Back to Top